Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 630

1.

Exosomal pMHC-I complex targets T cell-based vaccine to directly stimulate CTL responses leading to antitumor immunity in transgenic FVBneuN and HLA-A2/HER2 mice and eradicating trastuzumab-resistant tumor in athymic nude mice.

Wang L, Xie Y, Ahmed KA, Ahmed S, Sami A, Chibbar R, Xu Q, Kane SE, Hao S, Mulligan SJ, Xiang J.

Breast Cancer Res Treat. 2013 Jul;140(2):273-84. doi: 10.1007/s10549-013-2626-7. Epub 2013 Jul 24.

PMID:
23881522
2.

Potent CD4+ T-cell epitope P30 enhances HER2/neu-engineered dendritic cell-induced immunity against Tg1-1 breast cancer in transgenic FVBneuN mice by enhanced CD4+ T-cell-stimulated CTL responses.

Xie Y, Chen Y, Ahmed KA, Li W, Ahmed S, Sami A, Chibbar R, Tang X, Tao M, Xu J, Xiang J.

Cancer Gene Ther. 2013 Oct;20(10):590-8. doi: 10.1038/cgt.2013.60. Epub 2013 Sep 20.

PMID:
24052129
3.

Novel CD8+ T cell-based vaccine stimulates Gp120-specific CTL responses leading to therapeutic and long-term immunity in transgenic HLA-A2 mice.

Nanjundappa RH, Wang R, Xie Y, Umeshappa CS, Xiang J.

Vaccine. 2012 May 21;30(24):3519-25. doi: 10.1016/j.vaccine.2012.03.075. Epub 2012 Apr 6.

PMID:
22484292
4.

Adjuvant effect of HER-2/neu-specific adenoviral vector stimulating CD8⁺ T and natural killer cell responses on anti-HER-2/neu antibody therapy for well-established breast tumors in HER-2/neu transgenic mice.

Chen Y, Xie Y, Chan T, Sami A, Ahmed S, Liu Q, Xiang J.

Cancer Gene Ther. 2011 Jul;18(7):489-99. doi: 10.1038/cgt.2011.18. Epub 2011 May 13.

PMID:
21566669
5.

GP120-specific exosome-targeted T cell-based vaccine capable of stimulating DC- and CD4(+) T-independent CTL responses.

Nanjundappa RH, Wang R, Xie Y, Umeshappa CS, Chibbar R, Wei Y, Liu Q, Xiang J.

Vaccine. 2011 Apr 27;29(19):3538-47. doi: 10.1016/j.vaccine.2011.02.095. Epub 2011 Mar 12.

PMID:
21406265
7.
8.

Efficient induction of a Her2-specific anti-tumor response by dendritic cells pulsed with a Hsp70L1-Her2(341-456) fusion protein.

Fu Q, Wu Y, Yan F, Wang N, Wang W, Cao X, Wang Y, Wan T.

Cell Mol Immunol. 2011 Sep;8(5):424-32. doi: 10.1038/cmi.2011.21. Epub 2011 Jul 25.

9.

Dendritic cells recruit T cell exosomes via exosomal LFA-1 leading to inhibition of CD8+ CTL responses through downregulation of peptide/MHC class I and Fas ligand-mediated cytotoxicity.

Xie Y, Zhang H, Li W, Deng Y, Munegowda MA, Chibbar R, Qureshi M, Xiang J.

J Immunol. 2010 Nov 1;185(9):5268-78. doi: 10.4049/jimmunol.1000386. Epub 2010 Sep 29.

10.
11.
13.

Ontak reduces the immunosuppressive tumor environment and enhances successful therapeutic vaccination in HER-2/neu-tolerant mice.

Gritzapis AD, Voutsas IF, Baxevanis CN.

Cancer Immunol Immunother. 2012 Mar;61(3):397-407. doi: 10.1007/s00262-011-1113-4. Epub 2011 Sep 18.

PMID:
21928125
14.

Peptide vaccination breaks tolerance to HER-2/neu by generating vaccine-specific FasL(+) CD4(+) T cells: first evidence for intratumor apoptotic regulatory T cells.

Gritzapis AD, Voutsas IF, Lekka E, Papamichail M, Baxevanis CN.

Cancer Res. 2010 Apr 1;70(7):2686-96. doi: 10.1158/0008-5472.CAN-09-2517. Epub 2010 Mar 16.

15.

The HER2/neu-derived peptide p654-662 is a tumor-associated antigen in human pancreatic cancer recognized by cytotoxic T lymphocytes.

Peiper M, Goedegebuure PS, Linehan DC, Ganguly E, Douville CC, Eberlein TJ.

Eur J Immunol. 1997 May;27(5):1115-23.

PMID:
9174600
16.

Investigating the combination of trastuzumab and HER2/neu peptide vaccines for the treatment of breast cancer.

Mittendorf EA, Storrer CE, Shriver CD, Ponniah S, Peoples GE.

Ann Surg Oncol. 2006 Aug;13(8):1085-98. Epub 2006 Jul 24.

PMID:
16865596
17.

Exosomes as potent cell-free peptide-based vaccine. I. Dendritic cell-derived exosomes transfer functional MHC class I/peptide complexes to dendritic cells.

André F, Chaput N, Schartz NE, Flament C, Aubert N, Bernard J, Lemonnier F, Raposo G, Escudier B, Hsu DH, Tursz T, Amigorena S, Angevin E, Zitvogel L.

J Immunol. 2004 Feb 15;172(4):2126-36.

18.

Active CD4+ helper T cells directly stimulate CD8+ cytotoxic T lymphocyte responses in wild-type and MHC II gene knockout C57BL/6 mice and transgenic RIP-mOVA mice expressing islet beta-cell ovalbumin antigen leading to diabetes.

Ye Z, Ahmed KA, Hao S, Zhang X, Xie Y, Munegowda MA, Meng Q, Chibbar R, Xiang J.

Autoimmunity. 2008 Nov;41(7):501-11. doi: 10.1080/08916930802069256.

PMID:
18855194
19.

A novel T cell-based vaccine capable of stimulating long-term functional CTL memory against B16 melanoma via CD40L signaling.

Xie Y, Wang L, Freywald A, Qureshi M, Chen Y, Xiang J.

Cell Mol Immunol. 2013 Jan;10(1):72-7. doi: 10.1038/cmi.2012.37. Epub 2012 Oct 8.

20.

A combination of chemoimmunotherapies can efficiently break self-tolerance and induce antitumor immunity in a tolerogenic murine tumor model.

Ko HJ, Kim YJ, Kim YS, Chang WS, Ko SY, Chang SY, Sakaguchi S, Kang CY.

Cancer Res. 2007 Aug 1;67(15):7477-86.

Supplemental Content

Support Center